Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$131.00
+1.0%
$130.63
$99.71
$141.23
$227.20B0.86.05 million shs10.46 million shs
Boston Scientific Co. stock logo
BSX
Boston Scientific
$95.08
-0.2%
$99.68
$66.80
$107.17
$140.63B0.736.37 million shs6.67 million shs
DexCom, Inc. stock logo
DXCM
DexCom
$68.59
-0.2%
$75.33
$57.52
$139.24
$26.90B1.54.21 million shs3.70 million shs
Medtronic plc stock logo
MDT
Medtronic
$82.58
-0.1%
$89.08
$75.96
$96.25
$105.91B0.796.67 million shs5.94 million shs
Roche Holding AG stock logo
RHHVF
Roche
$313.62
+2.0%
$326.95
$233.12
$354.19
N/AN/A4,412 shs105 shs
Stryker Co. stock logo
SYK
Stryker
$346.46
-0.1%
$371.83
$314.93
$406.19
$132.24B0.931.36 million shs1.35 million shs
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
$97.90
+1.0%
$105.95
$96.58
$123.96
$19.37B0.841.65 million shs4.37 million shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abbott Laboratories stock logo
ABT
Abbott Laboratories
+0.97%+5.34%+3.82%+15.47%+23.70%
Boston Scientific Co. stock logo
BSX
Boston Scientific
-0.21%+2.95%-4.13%-3.70%+39.90%
DexCom, Inc. stock logo
DXCM
DexCom
-0.20%+1.92%-2.98%-18.71%-48.76%
Medtronic plc stock logo
MDT
Medtronic
-0.21%+0.06%-10.34%-6.40%+4.43%
Roche Holding AG stock logo
RHHVF
Roche
+2.02%+6.12%-10.59%+8.63%+29.26%
Stryker Co. stock logo
SYK
Stryker
-0.07%-0.17%-7.89%-9.75%+3.10%
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
+0.82%-4.51%-13.20%-10.72%-19.29%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abbott Laboratories stock logo
ABT
Abbott Laboratories
4.8612 of 5 stars
2.44.04.24.53.92.52.5
Boston Scientific Co. stock logo
BSX
Boston Scientific
4.4364 of 5 stars
3.53.00.04.23.52.51.3
DexCom, Inc. stock logo
DXCM
DexCom
4.9053 of 5 stars
4.54.00.04.73.92.51.9
Medtronic plc stock logo
MDT
Medtronic
4.6863 of 5 stars
3.25.03.34.02.92.50.6
Roche Holding AG stock logo
RHHVF
Roche
0.1059 of 5 stars
0.02.01.70.00.00.00.0
Stryker Co. stock logo
SYK
Stryker
4.6843 of 5 stars
3.43.03.34.23.02.51.3
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
4.7361 of 5 stars
4.23.01.73.73.52.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.84
Moderate Buy$142.598.84% Upside
Boston Scientific Co. stock logo
BSX
Boston Scientific
3.04
Buy$110.2215.92% Upside
DexCom, Inc. stock logo
DXCM
DexCom
2.95
Moderate Buy$99.0044.33% Upside
Medtronic plc stock logo
MDT
Medtronic
2.44
Hold$96.1416.42% Upside
Roche Holding AG stock logo
RHHVF
Roche
0.00
N/AN/AN/A
Stryker Co. stock logo
SYK
Stryker
2.79
Moderate Buy$423.5322.24% Upside
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
2.32
Hold$124.1526.82% Upside

Current Analyst Ratings Breakdown

Latest DXCM, ABT, BSX, MDT, RHHVF, SYK, and ZBH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$133.00 ➝ $145.00
4/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$132.00 ➝ $142.00
4/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$140.00 ➝ $145.00
4/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$117.00 ➝ $127.00
4/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$136.00 ➝ $147.00
4/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$158.00 ➝ $159.00
4/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$135.00 ➝ $145.00
4/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$135.00 ➝ $137.00
4/16/2025
Boston Scientific Co. stock logo
BSX
Boston Scientific
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$113.00
4/14/2025
Stryker Co. stock logo
SYK
Stryker
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$403.00
4/14/2025
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 4/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$41.95B5.42$5.64 per share23.22$22.36 per share5.86
Boston Scientific Co. stock logo
BSX
Boston Scientific
$16.75B8.40$3.29 per share28.86$14.91 per share6.38
DexCom, Inc. stock logo
DXCM
DexCom
$4.03B6.67$1.73 per share39.75$5.38 per share12.75
Medtronic plc stock logo
MDT
Medtronic
$33.20B3.19$6.76 per share12.21$38.69 per share2.13
Roche Holding AG stock logo
RHHVF
Roche
N/AN/AN/AN/AN/AN/A
Stryker Co. stock logo
SYK
Stryker
$22.60B5.85$13.52 per share25.62$54.08 per share6.41
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
$7.68B2.52$12.47 per share7.85$62.67 per share1.56
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$13.40B$7.6517.1222.862.5231.95%20.74%11.19%N/A
Boston Scientific Co. stock logo
BSX
Boston Scientific
$1.85B$1.2576.0629.442.7911.07%17.80%9.85%4/23/2025 (Estimated)
DexCom, Inc. stock logo
DXCM
DexCom
$576.20M$1.4347.9727.882.3014.29%30.14%10.11%5/1/2025 (Estimated)
Medtronic plc stock logo
MDT
Medtronic
$3.68B$3.2925.1014.162.2212.83%14.07%7.70%5/21/2025 (Estimated)
Roche Holding AG stock logo
RHHVF
Roche
N/A$10.8129.01N/AN/AN/AN/AN/A
Stryker Co. stock logo
SYK
Stryker
$2.99B$7.7644.6523.362.9313.25%23.58%11.37%5/1/2025 (Estimated)
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
$903.70M$4.4522.0011.041.9511.77%12.99%7.58%5/5/2025 (Estimated)

Latest DXCM, ABT, BSX, MDT, RHHVF, SYK, and ZBH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/5/2025Q1 2025
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
$1.77N/AN/AN/A$1.89 billionN/A
5/1/2025Q1 2025
DexCom, Inc. stock logo
DXCM
DexCom
$0.33N/AN/AN/A$1.02 billionN/A
5/1/2025Q1 2025
Stryker Co. stock logo
SYK
Stryker
$2.76N/AN/AN/A$5.68 billionN/A
4/23/2025Q1 2025
Boston Scientific Co. stock logo
BSX
Boston Scientific
$0.67N/AN/AN/A$4.57 billionN/A
4/16/2025Q1 2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.07$1.09+$0.02$0.76$10.38 billion$10.36 billion
2/18/2025Q3 2025
Medtronic plc stock logo
MDT
Medtronic
$1.36$1.39+$0.03$1.01$8.33 billion$8.29 billion
2/13/2025Q4 2024
DexCom, Inc. stock logo
DXCM
DexCom
$0.50$0.45-$0.05$0.38$1.10 billionN/A
2/6/2025Q4 2024
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
$2.30$2.31+$0.01$1.20$2.01 billionN/A
2/5/2025Q4 2024
Boston Scientific Co. stock logo
BSX
Boston Scientific
$0.65$0.70+$0.05$0.38$4.42 billionN/A
1/28/2025Q4 2024
Stryker Co. stock logo
SYK
Stryker
$3.87$4.01+$0.14$1.41$6.36 billionN/A
1/22/2025Q4 2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.34$1.34N/A$5.27$11.03 billion$10.97 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.361.80%+7.17%30.85%54 Years
Boston Scientific Co. stock logo
BSX
Boston Scientific
N/AN/AN/AN/AN/A
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
Medtronic plc stock logo
MDT
Medtronic
$2.803.39%+4.14%85.11%48 Years
Roche Holding AG stock logo
RHHVF
Roche
$7.802.49%N/A72.16%N/A
Stryker Co. stock logo
SYK
Stryker
$3.360.97%+7.82%43.30%32 Years
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
$0.960.98%N/A21.57%N/A

Latest DXCM, ABT, BSX, MDT, RHHVF, SYK, and ZBH Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/21/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
quarterly$0.591.75%4/15/20254/15/20255/15/2025
2/5/2025
Stryker Co. stock logo
SYK
Stryker
quarterly$0.840.86%3/31/20253/31/20254/30/2025
2/26/2025
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
quarterly$0.240.89%3/31/20253/31/20254/30/2025
3/6/2025
Medtronic plc stock logo
MDT
Medtronic
quarterly$0.703%3/28/20253/28/20254/11/2025
3/21/2025
Roche Holding AG stock logo
RHHVF
Roche
$9.703.17%3/27/20253/28/20253/31/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.32
1.60
1.14
Boston Scientific Co. stock logo
BSX
Boston Scientific
0.41
1.08
1.02
DexCom, Inc. stock logo
DXCM
DexCom
0.59
1.47
1.28
Medtronic plc stock logo
MDT
Medtronic
0.48
1.90
1.39
Roche Holding AG stock logo
RHHVF
Roche
N/AN/AN/A
Stryker Co. stock logo
SYK
Stryker
0.59
1.95
1.32
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
0.43
1.91
0.99

Institutional Ownership

CompanyInstitutional Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%
Boston Scientific Co. stock logo
BSX
Boston Scientific
89.07%
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
Medtronic plc stock logo
MDT
Medtronic
82.06%
Roche Holding AG stock logo
RHHVF
Roche
29.01%
Stryker Co. stock logo
SYK
Stryker
77.09%
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
88.89%

Insider Ownership

CompanyInsider Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.46%
Boston Scientific Co. stock logo
BSX
Boston Scientific
0.50%
DexCom, Inc. stock logo
DXCM
DexCom
0.32%
Medtronic plc stock logo
MDT
Medtronic
0.20%
Roche Holding AG stock logo
RHHVF
Roche
N/A
Stryker Co. stock logo
SYK
Stryker
5.90%
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
0.95%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
115,0001.73 billion1.73 billionOptionable
Boston Scientific Co. stock logo
BSX
Boston Scientific
45,0001.48 billion1.47 billionOptionable
DexCom, Inc. stock logo
DXCM
DexCom
7,600392.11 million389.60 millionOptionable
Medtronic plc stock logo
MDT
Medtronic
95,0001.28 billion1.28 billionOptionable
Roche Holding AG stock logo
RHHVF
Roche
103,605N/AN/ANot Optionable
Stryker Co. stock logo
SYK
Stryker
51,000381.69 million359.07 millionOptionable
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
18,000197.84 million197.18 millionOptionable

Recent News About These Companies

Zimmer Biomet Holdings Becomes Oversold (ZBH)
Zimmer Biomet discloses pay packages for top executives and its median employee
Zimmer Biomet price target raised to $123 from $122 at BTIG

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Abbott Laboratories stock logo

Abbott Laboratories NYSE:ABT

$131.00 +1.30 (+1.00%)
Closing price 04/17/2025 03:59 PM Eastern
Extended Trading
$130.98 -0.03 (-0.02%)
As of 04/17/2025 06:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Boston Scientific stock logo

Boston Scientific NYSE:BSX

$95.08 -0.17 (-0.18%)
Closing price 04/17/2025 03:59 PM Eastern
Extended Trading
$96.52 +1.44 (+1.51%)
As of 04/17/2025 06:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

DexCom stock logo

DexCom NASDAQ:DXCM

$68.59 -0.14 (-0.20%)
Closing price 04/17/2025 03:59 PM Eastern
Extended Trading
$68.80 +0.20 (+0.29%)
As of 04/17/2025 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Medtronic stock logo

Medtronic NYSE:MDT

$82.58 -0.12 (-0.15%)
Closing price 04/17/2025 03:59 PM Eastern
Extended Trading
$82.50 -0.08 (-0.10%)
As of 04/17/2025 06:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Roche stock logo

Roche OTCMKTS:RHHVF

$313.62 +6.20 (+2.02%)
As of 04/17/2025 11:20 AM Eastern

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.

Stryker stock logo

Stryker NYSE:SYK

$346.46 -0.21 (-0.06%)
Closing price 04/17/2025 03:59 PM Eastern
Extended Trading
$352.48 +6.03 (+1.74%)
As of 04/17/2025 06:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.

Zimmer Biomet stock logo

Zimmer Biomet NYSE:ZBH

$97.90 +0.96 (+0.99%)
Closing price 04/17/2025 03:59 PM Eastern
Extended Trading
$98.03 +0.13 (+0.14%)
As of 04/17/2025 05:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers robotic, surgical, and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.